CN108324783A - 白归参灵冬甘治癌药 - Google Patents
白归参灵冬甘治癌药 Download PDFInfo
- Publication number
- CN108324783A CN108324783A CN201810310344.0A CN201810310344A CN108324783A CN 108324783 A CN108324783 A CN 108324783A CN 201810310344 A CN201810310344 A CN 201810310344A CN 108324783 A CN108324783 A CN 108324783A
- Authority
- CN
- China
- Prior art keywords
- parts
- cancer
- ginseng
- radix
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 152
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 128
- 201000011510 cancer Diseases 0.000 title claims abstract description 128
- 239000003814 drug Substances 0.000 title claims abstract description 124
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 78
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 78
- 229940079593 drug Drugs 0.000 title claims abstract description 59
- 241000208340 Araliaceae Species 0.000 title claims abstract 20
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 108
- 239000008280 blood Substances 0.000 claims abstract description 74
- 210000004369 blood Anatomy 0.000 claims abstract description 72
- 241000258920 Chilopoda Species 0.000 claims abstract description 54
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 54
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 54
- 241000756943 Codonopsis Species 0.000 claims abstract description 49
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 45
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 43
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 43
- 241000427159 Achyranthes Species 0.000 claims abstract description 39
- 240000001659 Oldenlandia diffusa Species 0.000 claims abstract description 37
- 230000001737 promoting effect Effects 0.000 claims abstract description 27
- 230000017531 blood circulation Effects 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000007924 injection Substances 0.000 claims abstract description 16
- 238000002347 injection Methods 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000006187 pill Substances 0.000 claims abstract description 9
- 238000002679 ablation Methods 0.000 claims abstract description 8
- 230000007423 decrease Effects 0.000 claims abstract description 8
- 230000032823 cell division Effects 0.000 claims abstract description 7
- 229940100688 oral solution Drugs 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims abstract description 7
- 229920002472 Starch Polymers 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 235000019698 starch Nutrition 0.000 claims abstract description 5
- 239000008107 starch Substances 0.000 claims abstract description 5
- 230000008569 process Effects 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 80
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 238000009835 boiling Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 244000025254 Cannabis sativa Species 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 abstract description 13
- 238000001959 radiotherapy Methods 0.000 abstract description 11
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 47
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- 210000004185 liver Anatomy 0.000 description 26
- 208000002193 Pain Diseases 0.000 description 24
- 230000002401 inhibitory effect Effects 0.000 description 24
- 230000036407 pain Effects 0.000 description 24
- 150000004676 glycans Chemical class 0.000 description 23
- 229920001282 polysaccharide Polymers 0.000 description 23
- 239000005017 polysaccharide Substances 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 230000006870 function Effects 0.000 description 22
- 231100000614 poison Toxicity 0.000 description 18
- 206010011224 Cough Diseases 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 206010003445 Ascites Diseases 0.000 description 14
- 230000012010 growth Effects 0.000 description 14
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 230000001093 anti-cancer Effects 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 239000007789 gas Substances 0.000 description 12
- 239000002574 poison Substances 0.000 description 12
- 241000207961 Sesamum Species 0.000 description 11
- 235000003434 Sesamum indicum Nutrition 0.000 description 11
- 201000001881 impotence Diseases 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 201000007270 liver cancer Diseases 0.000 description 9
- 208000014018 liver neoplasm Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 7
- 229960004949 glycyrrhizic acid Drugs 0.000 description 7
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 7
- 235000019410 glycyrrhizin Nutrition 0.000 description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 231100000862 numbness Toxicity 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 241000222336 Ganoderma Species 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 239000003337 fertilizer Substances 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- NCTHNHPAQAVBEB-WGCWOXMQSA-M sodium ferulate Chemical compound [Na+].COC1=CC(\C=C\C([O-])=O)=CC=C1O NCTHNHPAQAVBEB-WGCWOXMQSA-M 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 241000202807 Glycyrrhiza Species 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 208000006268 Sarcoma 180 Diseases 0.000 description 5
- 208000034189 Sclerosis Diseases 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000005907 cancer growth Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 230000001338 necrotic effect Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- -1 triterpene acids Chemical class 0.000 description 5
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 4
- 235000014375 Curcuma Nutrition 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 4
- 239000004378 Glycyrrhizin Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000003560 cancer drug Substances 0.000 description 4
- 239000000496 cardiotonic agent Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 4
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940098465 tincture Drugs 0.000 description 4
- 231100000611 venom Toxicity 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 235000007756 Akebia quinata Nutrition 0.000 description 3
- 240000008027 Akebia quinata Species 0.000 description 3
- 241000205585 Aquilegia canadensis Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000269420 Bufonidae Species 0.000 description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 3
- 244000020518 Carthamus tinctorius Species 0.000 description 3
- 244000164480 Curcuma aromatica Species 0.000 description 3
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 3
- 240000009138 Curcuma zedoaria Species 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000017443 Hedysarum boreale Nutrition 0.000 description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000545744 Hirudinea Species 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 241000245665 Taraxacum Species 0.000 description 3
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000002457 bidirectional effect Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- 235000021552 granulated sugar Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 239000002435 venom Substances 0.000 description 3
- 210000001048 venom Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 235000019509 white turmeric Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 244000061520 Angelica archangelica Species 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 241000131329 Carabidae Species 0.000 description 2
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000218176 Corydalis Species 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000244987 Daiswa polyphylla Species 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 241000167880 Hirundinidae Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 2
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010061533 Myotonia Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- 240000001359 Origanum dictamnus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 244000179560 Prunella vulgaris Species 0.000 description 2
- 235000010674 Prunella vulgaris Nutrition 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000219784 Sophora Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000270708 Testudinidae Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 208000009916 Yoshida Sarcoma Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 208000025036 lymphosarcoma Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000003307 reticuloendothelial effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical class OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 235000013073 Acorus gramineus Nutrition 0.000 description 1
- 244000001632 Acorus gramineus Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000031023 Amana edulis Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000722826 Ardisia Species 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000041806 Cacalia Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- 235000007519 Chimonanthus praecox Nutrition 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 description 1
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 235000001759 Citrus maxima Nutrition 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 102100022133 Complement C3 Human genes 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 241000660877 Coridius Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 235000018274 Cunila origanoides Nutrition 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 241000407170 Curcuma Species 0.000 description 1
- 241000218916 Cycas Species 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 240000004638 Dendrobium nobile Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000014866 Dictamnus albus Nutrition 0.000 description 1
- 240000003176 Digitaria ciliaris Species 0.000 description 1
- 235000017898 Digitaria ciliaris Nutrition 0.000 description 1
- 240000005717 Dioscorea alata Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 235000014693 Fagopyrum tataricum Nutrition 0.000 description 1
- 244000130270 Fagopyrum tataricum Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 241000935235 Fritillaria meleagris Species 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001475335 Ganoderma sp. Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 241000270288 Gekko Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000246500 Gentianella aspera Species 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- NJUXRKMKOFXMRX-RNCAKNGISA-N Ginsenoside Rg5 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NJUXRKMKOFXMRX-RNCAKNGISA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- 206010024557 Lip neoplasm malignant stage unspecified Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 240000003146 Lobelia chinensis Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 241001633628 Lycoris Species 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 241000623906 Lytta vesicatoria Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000005410 Mediastinal Neoplasms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 235000015987 Origanum dictamnus Nutrition 0.000 description 1
- 235000004383 Origanum vulgare subsp. vulgare Nutrition 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 1
- 241001530038 Pantherophis obsoletus Species 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000283966 Pholidota <mammal> Species 0.000 description 1
- 240000007332 Podocarpus macrophyllus Species 0.000 description 1
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 description 1
- 240000005860 Portulaca grandiflora Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 244000097577 Rhus javanica Species 0.000 description 1
- 235000010889 Rhus javanica Nutrition 0.000 description 1
- 241000501113 Sargentodoxa cuneata Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241001212228 Sesbania drummondii Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000107975 Strychnos nux-vomica Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- 244000297179 Syringa vulgaris Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 240000006688 Telosma cordata Species 0.000 description 1
- 235000017352 Telosma cordata Nutrition 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 244000290970 Tetrapanax papyrifer Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 235000008326 Trichosanthes anguina Nutrition 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 241000489523 Veratrum Species 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000036624 brainpower Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000035603 choleresis Effects 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000005321 cobalt glass Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- NJUXRKMKOFXMRX-AXUZFSSLSA-N ginsenoside Rg5 Natural products CC(=CCC=C(C)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@@H](O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@@H]4CC[C@@]23C)C NJUXRKMKOFXMRX-AXUZFSSLSA-N 0.000 description 1
- NJUXRKMKOFXMRX-UHFFFAOYSA-N ginsenoside Rz1 Natural products CC(C)=CCC=C(C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NJUXRKMKOFXMRX-UHFFFAOYSA-N 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002342 glycyrrhetinic acids Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- LWYXLXAMDLNBFQ-UHFFFAOYSA-N iso-6-Carnavalin Natural products CC(O)CCCCCCCCCCC1CCC(O)C(C)N1 LWYXLXAMDLNBFQ-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- YAFQFNOUYXZVPZ-UHFFFAOYSA-N liproxstatin-1 Chemical compound ClC1=CC=CC(CNC=2C3(CCNCC3)NC3=CC=CC=C3N=2)=C1 YAFQFNOUYXZVPZ-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 201000000349 mediastinal cancer Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N p-dimethylbenzene Natural products CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 210000004258 portal system Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- MOCOXAJEZKHXSF-IHMBCTQLSA-M sodium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MOCOXAJEZKHXSF-IHMBCTQLSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000008945 zhigancao decoction Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Abstract
本发明的白归参灵冬甘治癌药,包括抑制细胞分裂、活血化瘀、固本扶正的中药,配方为:由白花蛇舌草、当归、三七、人参、党参、西洋参、蟾蜍、蜈蚣、灵芝、冬虫夏草、牛膝、甘草组成,通过加水在非金属锅具中煎熬、蒸馏、过滤、加入淀粉工艺制成水剂、口服液、注射液、片剂或丸药。视患者体质强弱,用量增减人参、党参、西洋参的份量。视癌症轻重,可以适时增减蟾蜍、蜈蚣的份量。用于除孕妇以外的癌症中晚期患者在正规医院手术、化疗、放疗摘除肿瘤后的疗养和康复,清理癌细胞,固本扶正,恢复体质。
Description
技术领域 本发明的白归参灵冬甘治癌药涉及到医药领域,特别是一种治癌的中药,尤其是一种治癌药用于癌症中晚期化疗、放射、手术摘除肿瘤后的治疗和康复的中药。
背景技术 目前治癌的药物和专利都很多,几乎所有抗肿瘤的药物都是抑制肿瘤细胞的分裂。这样一来就太多了,比如5氟尿嘧啶,甲氨蝶呤,环磷酰胺,白消安,美法仑,卡莫司汀(卡氮芥)等等西药。但是西药副作用很大,常使患者脱发、虚脱破坏人体正常免疫力。用于癌症中晚期,化疗、放射、手术后的治疗和康复的中药很少,主要是夹竹桃科植物长春花中提取的有效成分的长春新碱抑制细胞分裂;虽然,长春新碱抗肿瘤作用良好,但是毒副作用大,主要是神经毒性。目前,治疗癌症没有副作用的西药没有,治疗癌症没有副作用的中药也没有。近些年“治癌药”专利也有一些,如:“一种含蜈蚣粉的治癌药(申请号CN201710973480.3)”,其特征在于含蜈蚣粉的治癌药由蜈蚣粉和砂糖组成;所述的蜈蚣粉和砂糖的质量百分比为:蜈蚣粉90%和砂糖10%。“一种黑乌莲生汁防癌治癌药物(申请号CN201010003058.3)”,其特征是它由黑乌莲生汁和药粉两部分组成,黑乌莲生汁的制法是将黑乌莲压榨取其生汁,再加入生汁重量1~5%的日本产纯玄米酢保鲜剂,混合均匀即可;药粉的制法是将原料按下列质量百分比进行配料,阿胶10~50%,西洋参15~55%,川贝母6~50%,肉苁蓉6~50%,龟胶6~50%,海马3~20%,蛤蚧3~20%,藏红花2~15%,藏茵陈2~15%,冬虫夏草0~5%,配料后把原料粉碎成粉状物再混合均匀得药粉。“一种中药治癌药物CN200810187541.4”其特征在于:所述中药治癌药物的组分按重量由双花80-120克、连翘80-120克、白鲜皮100-250克、蝎子30-60克、蜈蚣20-40条、壁虎80-150克、半枝莲80-150克、半边莲80-150克、三七30-60克、蒲公英100-200克、山枝20-50克、黄芩20-50克、黄芪80-150克、党参80-150克、当归80-120克、龙衣20-50克组成。“一种治癌药物及其制备方法(申请号CN200810070965.2)”其特征在于,所述的治癌药物选择以下各原料药在下述重量份范围进行组合配制而成:紫杉10~20份、芦根10~30份、蝉蜕3~8份、两面针10~20份、山花根5~15份、刺拐棒20~30份、大青5~15份、远志3~5份、猪苓5~15份、大红袍3~8份、龟甲10~20份、茯苓10~15份、瓜蒌5~15份、一枝蒿5~10份、半支莲20~30份、天南星5~10份、莪术5~10份、鸡血藤5~15份、青黛3~8份、夏枯草5~15份、蕲蛇3~8份、大黄10~20份、山豆根3~8份、蒲公英5~15份、重楼10~30份、鸦胆子3~8份、野灵芝20~40份、蜈蚣3~8份、虎杖3~8份、黄药子5~15份、木通10~20份、泽漆3~8份、通草5~10份、枸杞10~30份、白术10~30份、山地瓜20~40份、五味子3~8份、白花蛇舌草40~60份,石斛5~15份、党参20~40份、石菖蒲10~25份、石蒜10~25份、防风5~15份、野百合20~40份、紫杉醇1~3份。“抗肿瘤、抗癌药物(申请号CN200710065656.1)”一种抗淋巴癌、乳腺癌、肺癌、肝癌、胃癌、肠癌的药物,其特征在于它是由下列质量配比的原料制成的药剂:三七300-700份 蜈蚣50-100份 苦石莲400-600份 穿山甲300-600份 地鳖虫300-600份 乌蛇400-500份 郁金500-700份 九香虫200-300份。“治癌药(申请号CN200610054871.7)”山慈姑6g 马钱4g 斑蝥0.36g 土鳖15g 露蜂房20g 银花20g 花粉20g 当归20g 赤芍20g 浙贝20g 白芷20g 乳香20g 没药20g 元胡25g 天丁20g 地丁25g 蒲公英25g 川芎20g 白术20g 柴胡20g 枳实20g 桃仁20g 红花15g 海藻25g 昆布25g 玄参20g 夏枯草20g 丹参20g 牡蛎30g 鳖甲25g三棱15g 莪术20g 白花蛇舌草25g 半枝莲25g 人参20g 黄芪30g 神曲20g 山楂20g 等药组成,前四味药研细,分6次吞服,余药水煎,2日6次服完。癌症晚期恶化转移。剧痛的加一枝蒿0.04g元胡6g共研细一日2次服完,有特效。“一种中药治癌药物(申请号CN02133766.7)”其特征在于按重量份它由苦荞头30~50 大血藤10~30 小罗伞10~25 竹黄3~6 铁树叶15~30 山豆根10~30 杉木片15~30 八月札10~30 木通10~30 防己5~10 过山龙10~20 白薇10~20 芦荟10~30 鸡矢藤15~30 棕榈片15~30 芦根10~20 柚子叶10~20 生姜3~5组成。“一种抗癌治癌药物及其制备方法(申请号CN01129458.2)”,其特征在于它是以氯化钙、人参和乙醇为原料,经溶解、提取、混合、加热制成,其中各原料的重量配比是:氯化钙160-200g 人参280-320g 乙醇550-650ml。“一种治癌药物胶囊及其制备方法(申请号CN99125954.8)”其特征在于:它是由下述重量配比的原料制成1万粒:Ge-132 250g、人参500g、白术500g、茯苓500g、熟地500g、白芍500g、当归500g、川芎500g、黄芪500g、刺五加500g、甘草250g。“治癌药品(申请号CN99125228.4)”,主要由白花舌蛇草12~20份,莪术20~30份,狼毒15~25份,桃仁10~20份,红花5~15份,三棱20~30份,水蛭25~35份,蚤休10~20份,虻虫15~25分,赤芍10~20份,丹参10~20份,当归10~20份,芫花5~15份,经常规工艺提取而成。上述治癌药的中药用量大,药种复杂,药性猛、毒性大,没有解毒药,副作用难以控制。众所周知,癌证早期,人们很难发现,即使发现早期癌症信号,人们也不会轻易对症服用上述治癌药;一旦发现癌症就到了中晚期,就必须去正规医院手术、化疗、放疗摘除肿瘤,在肿瘤没有彻底清除时,癌症患者一般会疼痛、虚脱、消瘦、厌食,在家里长期服用上述以毒攻毒治癌猛药,仅仅以毒攻毒治疗癌症,没有给患者补充体质,又没有辅药化解药毒,都是非常危险的。但是,在医院手术、化疗、放疗也有副作用:患者自身免疫系统也受到不同程度的损伤,尤其是放疗、化疗后,很容易受到致病菌的感染导致死亡;并且癌细胞没有清除干净,不久还会复发。本发明的白归参灵冬甘治癌药则适用于癌症中晚期,在医院手术、化疗、放疗治疗摘除肿瘤后的疗养康复,清理癌细胞,固本扶正,恢复体质。
发明内容 本发明的目的旨在提供一种治癌药,能在癌症中晚期,在医院手术、化疗、放疗治疗摘除肿瘤后的疗养和康复,达到清理癌细胞,固本扶正,恢复体质的效果。
本发明的目的是这样实现的:因为癌症种类很多:血癌(白血病)、骨癌、淋巴癌(包括淋巴细胞瘤)、肠癌、肝癌、胃癌、盆腔癌(包括子宫癌,宫颈癌)、肺癌(包括纵隔癌)、脑癌、神经癌、乳腺癌、食道癌、肾癌等。身体各部位组织器官,除了毛发、指(趾)甲,都可能得癌症。参照WHO制定的统一分类标准ICD-10(国际疾病分类),这个标准中对已知的所有癌症都详细列举出来:ICD-10中关于恶性肿瘤的分类从C00-C97一共有88种(无C27、C28、C29、C35、C36、C42、C59、C86、C87、C89),还有亚型(比如C00又分C00.0-C00.9)的情况,那就更多了。众所周知,恶性肿瘤的差异较大,不同的患者表现不同,并没有固定的时间症状,癌症早期到中晚期发展时间不能一概而论,因每个人体质病情发展不同,因此时间的长短也不相同。早期恶性肿瘤多无明显全身症状。癌证早期,人们很难发现,人们不会轻易服用上述治癌药;一旦发现癌症就到了中晚期,应该及早治疗,患者就必须去正规医院手术、化疗、放疗。但是癌症患者在接受治疗的同时,其自身免疫系统也受到不同程度的损伤,尤其是放疗、化疗后,很容易受到致病菌的感染导致死亡;癌细胞没有清除干净,不久还会复发。癌证主要临床表现:(1)肿块癌细胞恶性增殖所形成的;(2)疼痛肿瘤的膨胀性生长或破溃、感染等使末梢神经或神经干受刺激或压迫,可出现局部疼痛。出现疼痛往往提示癌症已进入中、晚期;(3)溃疡体表或胃肠道的肿瘤,若生长过快,可因供血不足出现组织坏死或因继发感染而形成溃烂;(4)出血癌组织侵犯血管或癌组织小血管破裂而产生;(5)梗阻癌组织迅速生长而造成空腔脏器的梗阻;(6)肿瘤的转移癌细胞可通过直接蔓延、淋巴、血行和种植四种方式转移至临近和远处组织器官。①直接蔓延为癌细胞浸润性生长所致,与原发灶连续;②淋巴道转移多数情况为区域淋巴结转移,但也可出现跳跃式不经区域淋巴结而转移至远处的;③血行转移为肿瘤细胞经体循环静脉系统、门静脉系统、椎旁静脉系统等播散其他组织器官;④种植性转移为肿瘤细胞脱落后在体腔或空腔脏器内的转移。(7)其他颅内肿瘤可引起视力障碍(压迫视神经)、面瘫(压迫面神经)等多种神经系统症状;骨肿瘤侵犯骨骼可导致骨折;肝癌引起血浆白蛋白减少而致腹水等。肿瘤转移可以出现相应的症状,如区域淋巴结肿大,肺癌胸膜转移引起的癌性胸水等等。虽然,癌症发病原因与遗传、环境和吸烟、酗酒、吸入有毒重金属和致癌物等因素有关,癌症的种类也很繁多、复杂。但是癌症共同的特征是肿瘤,是癌细胞特异生长,阻碍了正常细胞组织器官生理机能、血液循环、新陈代谢,严重影响人们正常的生活、工作和身体健康及其生命安全。因此,治疗癌症时必须摘除肿瘤、抑制癌细胞生长、激活血液循环,保障正常的新陈代谢,恢复生理机能。为此:本发明的治癌药是用于摘除肿瘤之后的抑制癌细胞生长、激活血液循环,保障正常的新陈代谢,恢复生理机能的清理癌细胞,固本扶正,恢复体质的疗养和康复类药物。本发明的治癌药是由抑制细胞分裂、活血化瘀、固本扶正的中药组成,配方为:白花蛇舌草、当归、三七、人参、党参、西洋参、蟾蜍、蜈蚣、灵芝、冬虫夏草、牛膝、甘草。通常情况:白花蛇舌草15份、当归10份、三七粉6份、人参3份、党参10份、西洋参5份、蟾蜍粉1份、蜈蚣粉1份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份,按比例入500份水在非金属锅具中文火煎熬至沸腾,降温后制成。其中三七粉、蟾蜍粉、蜈蚣粉包煎,人参、党参、西洋参、灵芝、冬虫夏草另煎。混合后服用。视患者体质强弱,用量增减人参、党参、西洋参的份量。视癌症轻重,可以适时增减蟾蜍、蜈蚣的份量。通过加水煎熬、蒸馏、过滤、加入淀粉工艺制成水剂、口服液、注射液、片剂或丸药。用于患者正规医院手术、化疗、放疗摘除肿瘤后的疗养和康复,清理癌细胞,固本扶正,恢复体质。
由于采用了上述方案,因为本发明的白归参灵冬甘治癌药:
白花蛇舌草(根据360百科)能抑制细胞分裂,主治:肺热喘咳;咽喉肿痛;肠痈;疖肿疮疡;毒蛇咬伤;热淋涩痛;水肿;痢疾;肠炎;湿热黄疸;擅长治疗多种癌肿。用法与用量:内服:煎汤,15-30g,大剂量可用至60g。药理作用:1、增强免疫功能;白花蛇舌草体外试验表明本品抗菌效价很低,但内服后抗感染作用明显,系通过刺激网状内皮系统,增加白细胞吞噬功能以提高血清杀菌力,给药组白细胞吞噬刚果红的能力较对照组提高4倍。镜检可见网状内皮系统显著增生,网状细胞增生肥大,胞浆丰富,吞噬活跃,淋巴结、脾、肝等组织中嗜银物质呈致密化改变,显示机体防御功能加强。能增强体液免疫功能,使小鼠脾脏中溶血空斑数显著增加。2、抑瘤作用,白花蛇舌草在体内对白血病细胞如急性粒细胞白血病细胞、急性淋巴性白血病细胞有抑制作用;白花蛇舌草素对小白鼠腹水肝癌细胞有抑制、杀灭作用,1毫克白花蛇舌草素于24小时内可使0.2毫升腹水肝癌细胞全部死亡。白花蛇舌草在体内对大鼠瓦克癌256、小鼠宫颈癌14、肉瘤180、肝癌实体型、艾氏腹水癌腹水型转皮下型均有抑制作用。白花蛇舌草能使小鼠肉瘤180细胞分裂相尤其是有丝分裂相显著抑制、瘤组织坏死。所含三萜酸类对淋巴肉瘤1号腹水型、宫颈癌14、肝癌实体型、肉瘤180,香豆精类对子宫颈癌14、肉瘤180、肝癌实体型、多糖类对淋巴肉瘤1号腹水型、艾氏腹水癌皮下型,均有显著抑制作用,认为白花蛇舌草是一种广谱抗癌药,所含抗瘤成分不是一种。故用白花蛇舌草素治疗的肉瘤180小鼠,除肿瘤细胞受抑制外,肿瘤周围组织有淋巴细胞、中性粒细胞浸润、淋巴结、脾网状内皮细胞增生及肝中淋巴灶形成,枯氏细胞增生肥大明显。
当归(根据360百科):补血养血,当归味甘而重,故专能补血,为补血第一药,适用于心肝血虚证所致的面色苍白或萎黄、倦怠乏力、唇甲浅淡无华、头晕目眩、心悸失眠等症。调经活血,当归气轻而辛,故又能行血,既可通经调经,又能活络止痛。抗癌作用,当归可广泛用于各种肿瘤,尤其是妇科肿瘤,以气血停滞、瘀血凝聚者最宜。对血虚羸瘦的中晚期癌症或手术、放疗、化疗后正气虚弱之患者,亦可选用当归,以扶正抗癌。抗血栓作用,徐理纳等报道,当归及其阿魏酸钠有明显的抗血栓作用。大鼠实验表明,当归可使血栓干重量显著减少,血栓增长速度较对照组下降。徐俊杰报道,急性缺血性脑中风病人经当归治疗后,血液粘滞性降低,血浆纤维蛋白原减少,凝血酶原时间延长,红细胞和血小板电泳时间缩短。血液流变学研究表明,当归可能通过降低血浆纤维蛋白原浓度,增加细胞表面电荷,而促进细胞解聚,降低血液粘度。对造血系统的影响,其抗贫血作用可能与所含的维生素B12、烟酸、亚叶酸及生物素、叶酸等成分有关。较近的研究表明,阿魏酸钠有抗O2及H2O对红细胞的氧化作用,使膜脂质过氧化产物MDA减少,可明显降低由MDA引起的溶血作用。在阿魏酸钠存在下,镰刀型贫血患者红细胞脂质过氧化物MDA随阿魏酸钠浓度增加而减少,阿魏酸钠可明显降低补体溶血,抑制补体3b(C3b)与红细胞膜的结合;对补体激活及红细胞变性无影响。当归是中医补血、活血要药。实验研究证明,当归多糖能增加外周血红细胞、白细胞、血红蛋白及骨髓有核细胞数,这种作用特别是在外周血细胞减少和骨髓受到抑制时尤为明显。当归多糖可能是当归中促进造血的有效成分之一。
三七(根据360百科),祛瘀止痛,消炎解毒,祛腐生肌,保肝,三七具有抗肝损伤作用,三七也具有抗肝纤维化作用,对二甲基亚硝胺中毒大鼠肝损伤,以三七粉治疗4周,使肝细胞变性坏死减轻,肝细胞间胶原纤维减少。对CCl4中毒肝纤维化大鼠,在给CCl4造型的同时,口服三七粉进行防治9周,可减轻肝脏脂肪变性、炎症细胞浸润、肝细胞变性坏死。减少成纤维细胞和胶原的增生。三七具有一定的利胆作用,三七注射液对a-异硫氰酸萘酯引起的家兔肝内阻塞性黄疸具有显著降低血清胆红素,促进胆汁分泌作用。三七促进肝脏蛋白质合成,增加3H-TdR对受损肝脏DNA的掺入速率,增加3H-亮氨酸对肝脏蛋白质的掺入速率。抗肿瘤,人参皂苷Rh1对离体肝癌细胞有抑制作用。人参皂苷Rh可抑制小鼠黑色素瘤(B16)的生长,作用呈浓度依赖关系。三七皂苷在与刀豆蛋白(ConA)或植物血凝素(PHA)同时存在时,其诱导的小鼠脾细胞具有较强的抗瘤活性,可能是PNS增强了被激活的免疫细胞的杀伤能力。镇痛,三七为治疗跌打损伤的常用药,有确切的镇痛作用。对小鼠扭体法、热板法及大鼠光辐射甩尾法等多种疼痛模型有镇痛作用。镇痛有效成分为人参二醇皂苷。止血作用,能缩短凝血时间;有显著抗凝血作用,能抑制血小板凝聚,促进纤溶,并使全血粘度下降;能增加冠脉流量,降低心肌耗氧量,增加心输出量,并有抗心律失常作用;有镇静、镇痛及抗炎作用;有保肝、调节糖代谢、抗衰老及肮肿瘤作用;有增强肾上腺皮质功能的作用。
人参(根据360百科),抗肿瘤作用,人参中的人参皂苷中有抗肿瘤的作用的物质成分,人参皂苷rh2、人参皂苷rh1、人参皂苷rg3和人参皂苷rg5都有一定的抗肿瘤活性。人参皂苷Rh2是人参中抗肿瘤功效最好的成分。
党参(根据360百科),具有补中益气,健脾益肺之功效。党参有增强免疫力、扩张血管、降压、改善微循环、增强造血功能等作用。此外对化疗放疗引起的白细胞下降有提升作用。
西洋参(根据360百科),具有滋阴补气,宁神益智及清热生津,降火消暑的双重功效。古语云:″西洋参性凉而补,凡欲用人参而不受人参之温者皆可用之″。故补而不燥是西洋参的特别之处。1、强化心肌及增强心脏之活动能力。2、强壮中枢神经,安定身心并恢复疲劳,有镇静及解酒作用,增强记忆能力,对老人痴呆症有显著功效。3、对血压有调整作用,使暂时性或持久性血压下降.抑制动脉硬化并促进红血球生长,增加血色素的份量。4、能调节胰岛之分泌,因此对糖尿病有功效。5、对肝脏有调节毒素之分泌,促进新陈代谢的作用。6、能增强体力并对运动员具极大助益。7、抑制癌细胞生长,增加免疫功能。8、助长消化,对慢性胃病和肠胃衰弱有助效。
蟾蜍(根据360百科),对治疗食道癌、肝癌、肾炎、白喉、流行性肋腺炎均有很好的疗效。蟾酥含多种生物成分,有解毒、消肿、止痛功效。现代医学发现它有其他药物不可替代的强心、利尿、抗癌、麻醉、抗辐射、增加白血球的作用,是治疗冠心病良药,日本用蟾酥生产出″救生丹″良药。中国用蟾酥生产出六神丸、心宝、梅花点舌赃、华蟾素、天力蟾衣胶囊等药物。
蜈蚣(根据360百科),抗肿瘤作用,蜈蚣水蛭注射液对肿瘤细胞有抑制作用,它能使小鼠的精原细胞发生坏死、消失.蜈蚣水蛭对小鼠肝癌瘤体的抑制率为26%,属于微效,对网状内皮细胞机能有增强作用,但长期应用对肝脏有损伤.化癌丹(含昆布、海藻、龙胆草、全蝎、蜈蚣、醋炒大米等),对小鼠艾氏腹水癌有抑制作用。
灵芝(根据360百科),可用于治疗慢性中毒、各类慢性肝炎、肝硬化、肝功能障碍。1、灵芝味甘苦、性平,归心、肺、肝、脾经;可养心安神,养肺益气,理气化淤、滋肝健脾。主治虚劳体弱,神疲乏力,心悸失眠,头目昏晕,久咳气喘,食欲不振,反应迟钝,呼吸短促等症。2、灵芝含有的“锗”,能使人体血液吸收氧的能力增加1.5倍,因此可以促进新陈代谢并有延缓老化的作用,还有增强皮肤本身修护功能的功效,可用于各种慢性病所致的面色黄萎及由于气血不足而致的面部光泽等症;灵芝所含有机锗可诱导人体产生并激活NK细胞和巨噬细胞活性,参与免疫调节。3、灵芝中的多糖具有双向调节机体免疫力,抗肿瘤和护肝的作用;灵芝中的生物碱可以抗炎镇痛;灵芝孢子粉能止血、排毒、抗氧。药理作用,1、对中枢神经系统的作用:灵芝酊、灵芝发酵浓缩液、菌丝体醇提取液及孢子粉脱脂后的醇提取物腹腔注射时均可减少小鼠自发活动。2、对心血管系统的作用:灵芝酊对离体蟾蜍心脏有强心作用,家兔腹腔注射赤芝酊可使心收缩力加强,心率变化不大,腹腔注射灵芝醇提取物,对垂体后叶素引起的兔心电图T波高耸有明显对抗作用,表明其对急性心肌缺血有一定对抗。3、抗血小板聚集及抗血栓作用:灵芝注射液在体外对ADP和胶原诱导的人血小板聚集有明显抑制作用,健康人每日服紫芝0.2克共1星期,对ADP诱导的血小板聚集也有明显抑制,对胶原诱导者作用较差。心肌梗死或脑梗死患者服灵芝2星期,体内外试验均能抑制ADP诱导的血小板聚集,服药后对体外血栓形成也有明显抑制作用。4、对呼吸系统的作用:小鼠气管酚红排泌实验证明,灵芝醇提取液及灵芝(Ganoderma sp.)发酵液腹腔注射均有祛痰作用。5、对代谢和内分泌功能的影响:小鼠腹腔注射灵芝多糖BN3C(即D6)能促进血清、肝脏及骨髓的蛋白质与核酸的合成,加速骨髓细胞分裂、增殖,还能增加小鼠肝匀浆细胞P-450的含量,提高肝脏的解毒功能。灵芝浸膏对烫伤动物可增加血浆皮质醇的含量。6、保肝作用:小鼠灌服灵芝酊能减轻四氯化碳中毒所致的肝病理损害。7、对实验性肌强直的作用:小鼠腹腔注射灵芝注射液,对2,4-二氯苯氧乙酸引起的实验性肌强直有明显降低醛缩酶的作用。8、抗氧化、延缓衰老作用:灵芝多糖GLA、GLB、GLC对超氧阴离子(O)自由基的产生和红细胞脂质过氧化均有抑制作用,并对羟基自由基(·OH)有清除作用,具有超氧化物歧化酶样活性,是灵芝延缓衰老的重要因素。9、抗炎作用:大鼠灌服人工和天然灵芝水煎酒沉浓缩物均可显着抑制角叉菜胶所致关节肿。10、抗肿瘤作用:灵芝子实体柄粗提取物对小鼠S180抑制率达87.6%,其成分含多糖和蛋白质。灵芝热水提出物中分离得多种多糖腹腔注射,对小鼠S180移植性肿瘤有抑制作用。口服则无效。11、免疫调节作用:灵芝中分离的蛋白多糖腹腔注射可使小鼠腹腔渗出液中的细胞、巨噬细胞、多形核白细胞增加,表明有免疫加强作用,对绵羊红细胞(SRBC)免疫小鼠的脾脏溶血空斑形成细胞数明显增加,此种多糖含半乳糖、葡萄糖和木糖。
冬虫夏草(根据360百科),抗癌,现代医学临床研究表明,冬虫夏草吞噬肿瘤细胞的能力是硒的4倍,冬虫夏草所含虫草素能明显增强红细胞粘附肿瘤细胞的能力,抑制肿瘤生长和转移,能明显提升白血球和血小板数量,迅速改善放化疗后的呕吐恶心、胃口差、头发脱落、失眠等症状。在中国,冬虫夏草生长于海拔4200高的西藏那曲地区,由于其天然虫草素含量较高,因此抗癌效果更为显著。在美国,已将冬虫夏草列为抗肿瘤新药,进入临床三期。中医药理,冬虫夏草首次记载使用是清代吴仪洛《本草丛新》,书中认为冬虫夏草性味甘,温。功能补肺益肾,化痰止咳。可用之于久咳虚喘,产后虚弱、阳痿阴冷等“虚”的病症。据研究:冬虫夏草主要含有冬虫夏草素、虫草冬虫夏草酸、腺苷和多糖等成分;冬虫夏草素能抑制链球菌、鼻疽杆菌炭疽杆菌等病菌的生长,又是抗癌的活性物质,对人体的内分泌系统和神经系统有好的调节作用;虫草酸能改变人体微循环,具有明显的降血脂和镇咳祛痰作用;虫草多糖是免疫调节剂,可增强机体对病毒及寄生虫的抵抗力。
牛膝(根据360百科).《药性论》:治阴痿,补肾填精,逐恶血流结,助十二经脉。《本草衍义补遗》:能引诸药下行。《本草正义》:牛膝,疏利泄降,所主皆气血壅滞之病,《本经》谓主寒湿,当从《御览》所引作伤寒。其治湿流关节之痿痹,四肢拘挛,膝痛不可屈伸,固疏通壅滞之专职,要非气血枯竭之拘急不遂,可以并论。然凡属痿痹,本有湿阻、血衰两层。湿阻者,惟在驱邪而使之流通,血衰者,亦必滋养而助其营运。则牛膝曲而能达,无微不至,逐邪者,固倚为君,养正者,亦赖以辅佐,所以痿弱痹着,骨痛筋挛诸证,皆不可一日无此也。逐血气者,即所以通其壅滞,治伤热火烂,亦所以助其流通,且即此而可知牛膝之性,偏于寒凉。故能主热伤火伤。则寒湿为病,必非其任,上文之误,更显然矣。能堕胎者,滑利下行之力也。《别录》疗伤中少气,亦以湿热壅窒,中气不宣者言之,非正气不充,清阳下陷者所宜。其主男子阴消,亦主热盛伤阴而言,非能补肝肾之真阴也。老人失溺,盖地道不通,而为癃闭之病,必非下元不固,遗尿溺床之候。其所谓补中续绝填骨髓,益精,利阴气诸说,皆壅滞既疏,正气自旺,万不可误认牛膝为填补之品。脑中痛者,多阳邪之上升,牛膝下行为顺,则气火自潜。腰脊痛,亦经隧之壅滞,牛膝宣通脉络,则关节自利。又主月水不通,血结等证。则固破瘀导滞之真谛,此皆当就疏通一层着想,则牛膝之真实功用昭昭矣。用药禁忌,凡中气下陷,脾虚泄泻,下元不固,梦遗失精,月经过多,及孕妇均忌服。1.《得配本草》:中气不足,小便自利,俱禁用。2.《品汇精要》:妊妇不可服。3.《本草经疏》:经闭未久,疑似有娠者勿用;上焦药中勿入;血崩不止者忌之。4.《本草通玄》:梦遗失精者,在所当禁。5.《本草正》:脏寒便滑,下元不固者当忌用之。6.《药品化义》:若泻痢脾虚而腿膝酸痛不宜用。
甘草(根据360百科),1.用于心气虚,心悸怔忡,脉结代,以及脾胃气虚,倦怠乏力等。前者,常与桂枝配伍,如桂枝甘草汤、炙甘草汤。后者,常与党参、白术等同用,如四君子汤、理中丸等。2.用于痈疽疮疡、咽喉肿痛等。可单用,内服或外敷,或配伍应用。痈疽疮疡,常与金银花、连翘等同用,共奏清热解毒之功,如仙方活命饮。咽喉肿痛,常与桔梗同用,如桔梗汤。3.用于气喘咳嗽。可单用,亦可配伍其他药物应用。如治湿痰咳嗽的二陈汤;治寒痰咳喘的苓甘五味姜辛汤;治燥痰咳嗽的桑杏汤;治热毒而致肺痈咳唾腥臭脓痰的桔梗汤;治咳唾涎沫的甘草干姜汤等。另风热咳嗽、风寒咳嗽、热痰咳嗽亦常配伍应用。4.用于胃痛、腹痛及腓肠肌挛急疼痛等,常与芍药同用,能显著增强治挛急疼痛的疗效,如芍药甘草汤。5.用于调和某些药物的烈性。如调味承气汤用本品缓和大黄、芒硝的泻下作用及其对胃肠道的刺激。另外,在许多处方中也常用本品调和诸药。7甘草有类似肾上腺皮质激素样作用。对组胺引起的胃酸分泌过多有抑制作用;并有抗酸和缓解胃肠平滑肌痉挛作用。8.甘草黄酮、甘草浸膏及甘草次酸均有明显的镇咳作用;祛痰作用也较显著,其作用强度为甘草酸〉甘草黄酮〉甘草浸膏。9.甘草还有抗炎,抗过敏作用,能保护发炎的咽喉和气管粘膜。甘草浸膏和甘草酸对某些毒物有类似葡萄糖醛酸的解毒作用。10.甘草常用来治疗随更年期而来的症状.因为甘草里含有甘草素,是一种类似激素的化合物,它有助于平衡女性体内的激素含量。11.甘草所含的次酸能阻断致癌物诱发肿瘤生长的作用。久服大剂量甘草,可引起浮肿。有关研究还发现,甘草制剂有损性功能,每天服用28克甘草,可导致男性的性欲降低和其它形式的性无能,停药4天后可恢复。甘草还可抑制皮质醇的转化,从而导致血压上升和低血钾症。因此,对于有性功能减退、高血压及浮肿的患者,不宜使用甘草。
本发明的白归参灵冬甘治癌药因白花蛇舌草、蟾蜍、蜈蚣、当归、三七、人参、党参、西洋参、灵芝、冬虫夏草、牛膝、甘草均能抑制癌细胞生长,能活血化瘀、逐腐生肌、增加人体免疫力。其中:白花蛇舌草、蟾蜍、蜈蚣为君药,抗癌消肿;当归、三七为臣药,活血化瘀,逐腐生肌;人参、党参、西洋参、灵芝、冬虫夏草为佐药、补气固本,抗癌扶正;牛膝、甘草为使药,引经行药、和药解毒。因本发明的治癌药标本兼治,血气同济,既以毒攻毒,又以药解毒;既活血化瘀,又逐腐生肌。尤其是当归、人参既补血,又补气;蟾蜍利水利尿、强心,冬虫夏草既能抑制肿瘤生长和转移,又能明显提升白血球和血小板数量,迅速改善放化疗后的呕吐恶心、胃口差、头发脱落、失眠等症状,又能润肺、止咳止痛。人参、党参、西洋参虽然都是补气,补益药,但是人参温补,偏于补阳;党参平补,既补血又补气;西洋参凉补、偏于滋阴。本发明中将人参、党参、西洋参在治癌药中配伍共同入剂,能补阳滋阴、既补血又补气,健脾益胃,滋润五脏;对中晚期癌症患者的身体能起到固本扶正的效果。本发明的治癌药每一味均是传统中药,经过几千年无数次验证,副作用小;没有十八反十九畏中药禁忌情形,能长期服用,能够有效地改善癌症患者的肿块、疼痛、溃疡、出血、梗阻和肿瘤的转移等症状,将癌细胞通过白花蛇舌草、蟾蜍、蜈蚣、当归、三七抑制生长、活血化瘀,由血液循环将死亡的癌细胞内消,再由牛膝、甘草利尿排毒,经泌尿系统排出;人参、党参、西洋参、灵芝、冬虫夏草抗癌固本,滋润五脏,补血补气,平衡阴阳,促进患者身体由虚脱转为健康。本发明比背景的治癌药更有效、更全面、更安全,更能疗养和康复身体。因而,本发明更有优越性,在治癌方面更具有积极效果。
具体实施方式 本发明的白归参灵冬甘治癌药是由抑制细胞分裂、活血化瘀、固本扶正的中药组成,配方为:白花蛇舌草、当归、三七、人参、党参、西洋参、蟾蜍、蜈蚣、灵芝、冬虫夏草、牛膝、甘草,通过加水在非金属锅具中煎熬、蒸馏、过滤、加入淀粉工艺制成水剂、口服液、注射液、片剂或丸药。
通常情况:白花蛇舌草15份、当归10份、三七粉6份、人参3份、党参10份、西洋参5份、蟾蜍粉1份、蜈蚣粉1份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份,按比例加入500份水在非金属锅具中文火煎熬至沸腾,降温后制成水剂。其中三七粉、蟾蜍粉、蜈蚣粉包煎,人参、党参、西洋参、灵芝、冬虫夏草另煎。混合后服用。
患者体质弱,增加人参2份、党参2份、西洋参2份。即:白花蛇舌草15份、当归10份、三七粉6份、人参5份、党参12份、西洋参7份、蟾蜍粉1份、蜈蚣粉1份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份。
癌症重,可以适时增加蟾蜍1份、蜈蚣1份。即:白花蛇舌草15份、当归10份、三七粉6份、人参3份、党参10份、西洋参5份、蟾蜍粉2份、蜈蚣粉2份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份。
本发明的白归参灵冬甘治癌药的口服液制法:白花蛇舌草15份、当归10份、三七粉6份、人参3份、党参10份、西洋参5份、蟾蜍粉1份、蜈蚣粉1份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份,按比例加入500份水在非金属锅具中文火煎熬至沸腾。其中三七粉、蟾蜍粉、蜈蚣粉包煎,人参、党参、西洋参、灵芝、冬虫夏草另煎。混合后过滤、蒸馏浓缩,降温后装瓶制成口服液。
本发明的白归参灵冬甘治癌药的注射液制法:白花蛇舌草15份、当归10份、三七粉6份、人参3份、党参10份、西洋参5份、蟾蜍粉1份、蜈蚣粉1份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份,按比例加入500份水在非金属锅具中文火煎熬至沸腾。其中三七粉、蟾蜍粉、蜈蚣粉包煎,人参、党参、西洋参、灵芝、冬虫夏草另煎。混合后过滤、蒸馏浓缩,降温后装瓶制成注射液。
本发明的白归参灵冬甘治癌药的片剂、丸药制法:白花蛇舌草15份、当归10份、三七粉6份、人参3份、党参10份、西洋参5份、蟾蜍粉1份、蜈蚣粉1份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份,按比例加入500份水在非金属锅具中文火煎熬至沸腾。其中三七粉、蟾蜍粉、蜈蚣粉包煎,人参、党参、西洋参、灵芝、冬虫夏草另煎。混合后蒸馏浓缩,加入淀粉制成片剂或丸药。
本发明的白归参灵冬甘治癌药的用途和适用范围:用于癌症中晚期在医院接受手术、化疗、放射摘除肿瘤后的患者疗养和康复。
本发明因含有参,忌茶、萝卜、五灵脂、藜芦,有很强的活血化瘀功能不适用于孕妇癌症患者。
凡与本发明相同、相似、等同的用药、配方和药剂,或者用量增减,均属于本发明的保护范围。
本发明的白归参灵冬甘治癌药药效:因白花蛇舌草、蟾蜍、蜈蚣、当归、三七、人参、党参、西洋参、灵芝、冬虫夏草、牛膝、甘草均能抑制癌细胞生长,能活血化瘀、逐腐生肌、增加人体免疫力。其中:白花蛇舌草、蟾蜍、蜈蚣为君药,抗癌消肿;当归、三七为臣药,活血化瘀,逐腐生肌;人参、党参、西洋参、灵芝、冬虫夏草为佐药、补气固本,抗癌扶正;牛膝、甘草为使药,引经行药、和药解毒。因本发明的治癌药标本兼治,血气同济,既以毒攻毒,又以药解毒;既活血化瘀,又逐腐生肌。尤其是当归、人参既补血,又补气;蟾蜍利水利尿、强心,冬虫夏草既能抑制肿瘤生长和转移,又能明显提升白血球和血小板数量,迅速改善放化疗后的呕吐恶心、胃口差、头发脱落、失眠等症状,又能润肺、止咳止痛。人参、党参、西洋参虽然都是补气,补益药,但是人参温补,偏于补阳;党参平补,既补血又补气;西洋参凉补、偏于滋阴。本发明中将人参、党参、西洋参在治癌药中配伍共同入剂,能补阳滋阴、既补血又补气,健脾益胃,滋润五脏;对中晚期癌症患者的身体能起到固本扶正的效果。本发明的白归参灵冬甘治癌药每一味均是传统中药,经过几千年无数次验证,副作用小;没有十八反十九畏中药禁忌情形,能长期服用,能够有效地改善癌症患者的肿块、疼痛、溃疡、出血、梗阻和肿瘤的转移等症状,将癌细胞通过白花蛇舌草、蟾蜍、蜈蚣、当归、三七抑制生长、活血化瘀,由血液循环将死亡的癌细胞内消,再由牛膝、甘草利尿排毒,经泌尿系统排出;人参、党参、西洋参、灵芝、冬虫夏草抗癌固本,滋润五脏,补血补气,平衡阴阳,促进患者身体由虚脱转为健康。
附药理、临床应用、疗效相关文献:
白花蛇舌草(根据百度百科):临床应用,用100%白花蛇舌草针剂肌肉注射,每次2毫升,每日3次,治疗子宫颈癌,胃癌、肝癌各1例,症情均有不同程度的改善。
蟾蜍,味腥、温,有毒。归心经,具有解毒、止痛、开窍等功效。中国民间中医医药研究开发协会编《癌症独特秘方》中载:蟾皮性味腥、凉、微毒,功能解毒、利水、消胀、主治各种肿癌。1999年经上海交大量子医学检测,特别对癌症、肝硬化、疼痛诸症的治疗有效含量成分超8千量价上(凡有8千量价以上有免疫功能成分)。华夏出版社《中华医药全典》中载:蟾衣毒较轻,主要用于疮疡肿毒及小儿疳积,现代常用治肿瘤。远方出版社《中草药大全》中介绍,蟾衣可治癌、白血病、淋巴瘤等。
蜈蚣(根据百度百科):临床应用,蜈蚣晒干研末,每日量约2~3条蜈蚣,分次服。或以蜈蚣100条制成200毫升注射液,每天用2~4毫升,于病灶基底部浸润注射。以上述方法治疗胃癌7例,治愈1例,显效2例,有效2例,无效2例;食道癌11例,显效4例,有效5例,无效2例;肺癌3例,无效;乳腺癌3例,显效2例,无效I例;皮肤癌3例,治愈2例,无效1例;唇腺癌1例,无效;子宫颈癌5例,有效5例。总有效率为65.12%。实践中观察到,本药对于癌肿溃疡患者疗效较明显,多在用药后1月内见到溃疡明显缩小。有2例皮肤癌患者经用蜈蚣注射液治疗(其余癌症均口服给药)25~30天后,即出现癌组织坏死脱落,病理科复查见癌细胞萎缩退化,代之以炎性细胞和结缔组织,可认为已达临床痊愈。蜈蚣用量最多有每日用至6条者。亦未见到毒性反应。
当归(根据百度百科)八大好处,补血养血,当归味甘而重,故专能补血,为补血第一药;抗癌作用当归可广泛用于各种肿瘤,尤其是妇科肿瘤,以气血停滞、瘀血凝聚者最宜;对血虚羸瘦的中晚期癌症或手术、放疗、化疗后正气虚弱之患者,亦可选用当归,以扶正抗癌。免疫作用,当归及其萃取物阿魏酸钠和当归多醣对单核-巨噬细胞系统有明显的刺激作用,对免疫功能低下的机体也有免疫调解和恢复作用。当归对健康人的淋巴细胞转化也有促进作用。
三七(根据互动百科)保健功能:1.扩张血管、降低血压,改善微循环,增加血流量,预防和治疗心脑组织缺血、缺氧症。2.促进蛋白质、核糖核酸(RNA)、脱氧核糖核酸(DNA)合成,强身健体。3.促进血液细胞新陈代谢,平衡调节血液细胞。4.双向调节中枢神经,提高脑力,增强学习和记忆能力。5.增强机体免疫功能,抗肿瘤。6.止血、活血化瘀。7.保肝、抗炎。8.延缓衰老。9.双向调节血糖、降低血脂、胆固醇、抑制动脉硬化。
人参(根据《纲目》):″治男妇一切虚证,发热自汗,眩晕头痛,反胃吐食,痎疟,滑泻久痢,小便频数,淋沥,劳倦内伤,中风,中暑,痿痹,吐血,嗽血,下血,血淋,血崩,胎前产后诸病。″
党参(根据《中华本草》):对免疫机能的影响,党参及其多糖可使巨噬细胞的数量增加,细胞体积增大,伪足多,吞噬能力增强;细胞内的DNA、RNA、糖类、ACP酶、ATP酶、酸性酯酶和琥珀脱氢酶活性均显着增强,经显微分光光度计测定,服药后,巨噬细胞内各种化学成分含量明显增加,与对照组呈显着性差异。党参还能明显促进ConA活化的淋巴细胞DNA和蛋白质的生物合成,促进DNA合成的最适浓度为100μg/ml。DNA合成的高峰在48小时,对白介素-2(IL-2)产生也有明显的增强作用。
西洋参(根据《西洋参的功效与作用及食用方法》)临床应用:西洋参具有滋阴补气,宁神益智及清热生津,降火消暑的双重功效。古语云:“西洋参性凉而补,凡欲用人参而不受人参之温者皆可用之”。故补而不燥是西洋参的特别之处。1、强化心肌及增强心脏之活动能力。2、强壮中枢神经,安定身心并恢复疲劳,有镇静及解酒作用,增强记忆能力,对老人痴呆症有显著功效。3、对血压有调整作用,使暂时性或持久性血压下降.抑制动脉硬化并促进红血球生长,增加血色素的份量。4、能调节胰岛之分泌,因此对糖尿病有功效。5、对肝脏有调节毒素之分泌,促进新陈代谢的作用。6、能增强体力并对运动员具极大助益。7、抑制癌细胞生长,增加免疫功能。8、助长消化,对慢性胃病和肠胃衰弱有助效。
灵芝(根据《中华本草》):抗肿瘤作用,赤芝子实体柄粗提取物对小鼠S180抑制率达87.6%,其成分含多糖和蛋白质。赤芝热水提出物中分离得多种多糖腹腔注射,对小鼠S180移植性肿瘤有抑制作用。口服则无效。人工培养赤芝菌丝体中分离的蛋白多糖也能抑制小鼠S180生长,并对羊红细胞免疫的小鼠,其脾脏空斑形成细胞数明显增加。认为多糖抗肿瘤作用是通过宿主介导,加强宿主免疫功能的结果而非通过其直接细胞毒作用。小鼠腹腔注射从赤芝中分离的多糖GL-1、GL-2或GL-3,每日5~20mg/kg,连续10d,对S180抑制率达42%~97%。赤芝中的葡聚糖和杂聚糖均有抗小鼠S180的作用。免疫调节作用,赤芝中分离的蛋白多糖腹腔注射可使小鼠腹腔渗出液中的细胞、巨噬细胞、多形核白细胞增加,表明有免疫加强作用,对绵羊红细胞(SRBC)免疫小鼠的脾脏溶血空斑形成细胞数明显增加,此种多糖含半乳糖、葡萄糖和木糖。白介素-2(IL-2)是重要的淋巴因子之一,在免疫调节网络中占重要地位,它主要由T辅助细胞产生,故IL-2的水平间接反映T细胞的功能。研究表明,在试管内,氢化可的松和环孢素A可明显抑制小鼠脾细胞产生IL-2。赤芝热水提取物能明显对抗上述两者的抑制作用,促进IL-2的产生,其作用与浓度相关。整体研究亦证明赤芝可促进脾细胞产生IL-2,即使在同时应用免疫抑制剂的条件下,IL-2的产生仍有显着增加。赤芝多糖成分BN3C能显着提高小鼠腹腔巨噬细胞吞噬鸡红细胞的能力,可轻微活化小鼠脾细胞,使其进入低水平增殖及IL-2产生,但远不能与ConA相比;当与Con A合用时,显着提高细胞增殖,但IL-2活性降低。BN3C作用的靶细胞有T、B及辅助细胞,BN3C可降低环磷酰胺对小鼠脾细胞增殖的抑制作用。灵芝多糖BN3A,BN3B和BN3C在体外均显着增加正常小鼠脾细胞IL-2的产生,可恢复老年小鼠脾细胞产生IL-2的能力,部分对抗氢化可的松或环孢素A对小鼠脾细胞IL-2产生的抑制。赤芝多糖促进IL-2的分泌并增强T细胞功能,在小鼠混合淋巴细胞培养模型中,对环孢素A、氢化可的松、丝裂霉素C、氟尿嘧啶和阿糖胞苷的免疫抑制作用均有不同程度的对抗,抑制较轻时可完全对抗使之恢复正常。
冬虫夏草(根据360百科)临床应用:临床上使用虫草素多为辅助治疗恶性肿瘤,症状得到改善的在91.7%以上;主要用于鼻癌、咽癌,肺癌,白血病,脑癌以及其他恶性肿瘤的患者。北冬虫夏草中虫草酸的含量为3.09克,野生的虫草为5.54克,虫草酸是一种D-甘露醇,甘露醇能提高血浆渗透压,导致组织内的水分进入血管内,从而减轻组织水肿,补充血浆。虫草酸多用于脑水肿,防治急性肾功能衰竭,有调节心、脑、血管的作用,促进人体的新陈代谢、改善人体的微循环、降血脂、降血压。虫草多糖的药理试验证明:虫草多糖具有抗肿瘤、抗传染病的功效、增强性功能、补肾壮阳、益精气、防止衰老、延年益寿;对老年人慢性支气管炎、肺源性心脏病有显著的功效。能提高肝脏的解毒能力,起到扶肝的作用。降血糖、降血脂,贫血的患者用于补血,增强脾脏的营养性血流量,虫草多糖、生物活性强,适应性广,还具耐缺氧、镇痛、镇静的作用。
牛膝(根据《医学衷中参西录》):牛膝,原为补益之品,而善引气血下注,是以用药欲其下行者,恒以之为引经。故善治肾虚腰疼腿疼,或膝疼不能屈伸,或腿痿不能任地。兼治女子月闭血枯,催生下胎。又善治淋疼,通利小便,此皆其力善下行之效也。然《别录》又谓其除脑中痛,时珍又谓其治口疮齿痛者何也?盖此等证,皆因其气血随火热上升所致,重用牛膝引其气血下行,并能引其浮越之火下行,是以能愈也。愚因悟得此理,用以治脑充血证,伍以赭石、龙骨、牡蛎诸重坠收敛之品,莫不随手奏效,治愈者不胜纪矣。为其性专下注,凡下焦气化不固,一切滑脱诸证皆忌之。《本草正义》:牛膝,疏利泄降,所主皆气血壅滞之病,《本经》谓主寒湿,当从《御览》所引作伤寒。其治湿流关节之痿痹,四肢拘挛,膝痛不可屈伸,固疏通壅滞之专职,要非气血枯竭之拘急不遂,可以并论。然凡属痿痹,本有湿阻、血衰两层。湿阻者,惟在驱邪而使之流通,血衰者,亦必滋养而助其营运。则牛膝曲而能达,无微不至,逐邪者,固倚为君,养正者,亦赖以辅佐,所以痿弱痹着,骨痛筋挛诸证,皆不可一日无此也。逐血气者,即所以通其壅滞,治伤热火烂,亦所以助其流通,且即此而可知牛膝之性,偏于寒凉。故能主热伤火伤。则寒湿为病,必非其任,上文之误,更显然矣。能堕胎者,滑利下行之力也。《别录》疗伤中少气,亦以湿热壅窒,中气不宣者言之,非正气不充,清阳下陷者所宜。其主男子阴消,亦主热盛伤阴而言,非能补肝肾之真阴也。老人失溺,盖地道不通,而为癃闭之病,必非下元不固,遗尿溺床之候。其所谓补中续绝填骨髓,益精,利阴气诸说,皆壅滞既疏,正气自旺,万不可误认牛膝为填补之品。脑中痛者,多阳邪之上升,牛膝下行为顺,则气火自潜。腰脊痛,亦经隧之壅滞,牛膝宣通脉络,则关节自利。又主月水不通,血结等证。则固破瘀导滞之真谛,此皆当就疏通一层着想,则牛膝之真实功用昭昭矣。
甘草(根据《中药大辞典》)药理作用:甘草次酸对大白鼠移植的OberlingGuerin骨髓瘤有抑制作用,甘草酸单铵盐、甘草次酸钠及甘草次酸衍化物之混合物,对小白鼠艾氏腹水癌及肉瘤均有抑制作用,即使口服亦有效。甘草甜素、甘草甙对大鼠腹水肝癌及小鼠艾氏腹水癌细胞能产生形态学上的变化,甘草甜素尚能抑制皮下移植的吉田肉瘤。《药品化义》:″甘草,生用凉而泻火,主散表邪,消痈肿,利咽痛,解百药毒,除胃积热,去尿管痛,此甘凉除热之力也。炙用温而补中,主脾虚滑泻,胃虚口渴,寒热咳嗽,气短困倦,劳役虚损,此甘温助脾之功也。但味厚而太甜,补药中不宜多用,恐恋膈不思食也。《中华本草》:″抗肿瘤作用:甘草酸对大鼠腹水肝癌及小鼠艾氏腹水癌(EAC)细胞能产生形态学上的变化,还能抑制皮下移植的吉田肉瘤,其单铵盐对小鼠艾氏腹水癌及肉瘤均有抑制作用,口服也有效。甘草次酸对大鼠的移植Oberling Guerin骨髓瘤有抑制作用,其钠盐在最大耐受剂量时对小鼠艾氏腹水癌(EAC)及肉瘤-45细胞的生长有轻微的抑制作用。甘草甙对大鼠腹水肝癌及小鼠艾氏腹水癌细胞能产生形态学上变化。大戟酯二萜醇(12-0-teTCMLIBade-canoylphorbol-13-acetate,TPA)对二甲苯蒽(DMBA)致小鼠皮肤癌的促发作用,可被甘草甜素显着抑制。
Claims (10)
1.一种白归参灵冬甘治癌药,包括抑制细胞分裂、活血化瘀、固本扶正的中药,其特征是:由白花蛇舌草、当归、三七、人参、党参、西洋参、蟾蜍、蜈蚣、灵芝、冬虫夏草、牛膝、甘草组成;通过加水在非金属锅具中煎熬、蒸馏、过滤、加入淀粉工艺制成水剂、口服液、注射液、片剂或丸药。
2.根据权利要求1所述的一种白归参灵冬甘治癌药,其特征是:白花蛇舌草15份、当归10份、三七粉6份、人参3份、党参10份、西洋参5份、蟾蜍粉1份、蜈蚣粉1份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份,按比例加入500份水在非金属锅具中文火煎熬至沸腾,降温后制成水剂;其中三七粉、蟾蜍粉、蜈蚣粉包煎,人参、党参、西洋参、灵芝、冬虫夏草另煎;混合后服用。
3.根据权利要求1所述的一种白归参灵冬甘治癌药,其特征是:患者体质弱,增加人参2份、党参2份、西洋参2份;即:白花蛇舌草15份、当归10份、三七粉6份、人参5份、党参12份、西洋参7份、蟾蜍粉1份、蜈蚣粉1份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份。
4.根据权利要求1所述的一种白归参灵冬甘治癌药,其特征是:癌症重,可以适时增加蟾蜍1份、蜈蚣1份;即:白花蛇舌草15份、当归10份、三七粉6份、人参3份、党参10份、西洋参5份、蟾蜍粉2份、蜈蚣粉2份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份。
5.根据权利要求1所述的一种白归参灵冬甘治癌药,其特征是:白花蛇舌草15克、当归10克、三七粉6克、人参3克、党参10克、西洋参5克、蟾蜍粉1克、蜈蚣粉1克、灵芝8克、冬虫夏草6克、牛膝6克、甘草6克,按比例加入500克水在非金属锅具中文火煎熬至沸腾;其中三七粉、蟾蜍粉、蜈蚣粉包煎,人参、党参、西洋参、灵芝、冬虫夏草另煎;降温后制成口服液,混合后服用。
6.根据权利要求1所述的一种白归参灵冬甘治癌药,其特征是:白花蛇舌草15份、当归10份、三七粉6份、人参3份、党参10份、西洋参5份、蟾蜍粉1份、蜈蚣粉1份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份,按比例加入500份水在非金属锅具中文火煎熬至沸腾;其中三七粉、蟾蜍粉、蜈蚣粉包煎,人参、党参、西洋参、灵芝、冬虫夏草另煎;混合后过滤、蒸馏浓缩,装瓶制成注射液。
7.根据权利要求1所述的一种白归参灵冬甘治癌药,其特征是:白花蛇舌草15份、当归10份、三七粉6份、人参3份、党参10份、西洋参5份、蟾蜍粉1份、蜈蚣粉1份、灵芝8份、冬虫夏草6份、牛膝6份、甘草6份,按比例加入500份水在非金属锅具中文火煎熬至沸腾;其中三七粉、蟾蜍粉、蜈蚣粉包煎,人参、党参、西洋参、灵芝、冬虫夏草另煎;混合后蒸馏浓缩,加入淀粉制成片剂、丸药。
8.一种白归参灵冬甘治癌药的用途,其特征是:用于癌症中晚期在医院接受手术、化疗、放射摘除肿瘤后的患者疗养和康复。
9.根据权利要求8所述的一种白归参灵冬甘治癌药的用途,其特征是:不适用于孕妇癌症患者。
10.根据权利要求8所述的一种白归参灵冬甘治癌药的用途,其特征是:视患者体质和癌症轻重,增减用量。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810310344.0A CN108324783A (zh) | 2018-03-28 | 2018-03-28 | 白归参灵冬甘治癌药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810310344.0A CN108324783A (zh) | 2018-03-28 | 2018-03-28 | 白归参灵冬甘治癌药 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108324783A true CN108324783A (zh) | 2018-07-27 |
Family
ID=62932885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810310344.0A Pending CN108324783A (zh) | 2018-03-28 | 2018-03-28 | 白归参灵冬甘治癌药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108324783A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230160977A (ko) | 2022-05-17 | 2023-11-27 | 에이치앤오바이오시스(주) | 항암 치료에 사용되는 5종 이상의 생약 추출물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742866A (zh) * | 2004-08-31 | 2006-03-08 | 蔡绪旺 | 一种抗癌中药胶囊制剂 |
CN1876159A (zh) * | 2006-04-28 | 2006-12-13 | 钟龙 | 治肿瘤的中药的制备方法及其制备的中药 |
CN102283867A (zh) * | 2011-08-04 | 2011-12-21 | 陈宥伯 | 一种治疗癌症的中药组合物 |
-
2018
- 2018-03-28 CN CN201810310344.0A patent/CN108324783A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742866A (zh) * | 2004-08-31 | 2006-03-08 | 蔡绪旺 | 一种抗癌中药胶囊制剂 |
CN1876159A (zh) * | 2006-04-28 | 2006-12-13 | 钟龙 | 治肿瘤的中药的制备方法及其制备的中药 |
CN102283867A (zh) * | 2011-08-04 | 2011-12-21 | 陈宥伯 | 一种治疗癌症的中药组合物 |
Non-Patent Citations (2)
Title |
---|
刘承炜: "九九丹合十全大补汤治疗恶性肿瘤2例", 《航空航天医药》 * |
谢秋声;等: "左足底鳞状上皮细胞癌1例治验", 《上海中医药杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230160977A (ko) | 2022-05-17 | 2023-11-27 | 에이치앤오바이오시스(주) | 항암 치료에 사용되는 5종 이상의 생약 추출물 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102784363B (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
CN107929420A (zh) | 改善人体气血功能和提高免疫力的中药组合物和检测方法 | |
CN103099833A (zh) | 有助于缓解运动疲劳和延缓衰老的软胶囊及其制备方法 | |
KR20130104692A (ko) | 산사육 추출물을 함유하는 비만치료 및 예방용 조성물 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN107519310B (zh) | 提高精力抑制肿瘤细胞生长功能的中药组合物和制备工艺 | |
CN106215118A (zh) | 抗肿瘤的保健制剂及其制备方法 | |
CN102940808A (zh) | 一种用于治疗肺癌的组方药物及制备方法 | |
CN108324783A (zh) | 白归参灵冬甘治癌药 | |
CN104825821A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN101524473B (zh) | 虫草抗癌长寿丹及其制备方法 | |
CN114177261A (zh) | 一种防治慢性病及抗癌保健的中草药配方 | |
CN104825817B (zh) | 一种具有抗肿瘤作用的中药制剂 | |
CN104162093A (zh) | 治疗乳腺癌的中药制剂及其制备方法 | |
CN103110684A (zh) | 对胃黏膜有辅助保护作用软胶囊及其制备方法 | |
CN111084878A (zh) | 一种用于肺及呼吸系统疾病的生物医药、医用全营养食品及制备方法 | |
CN109771567A (zh) | 一种中草药扶正化瘀排毒化肿瘤的配方 | |
CN104225004B (zh) | 一种含巴西人参的辅助抗肿瘤中药制剂 | |
CN104524359B (zh) | 一种中药组合物、其制备方法及应用 | |
CN108452079B (zh) | 延缓衰老抑制肿瘤细胞生长及改善微循环的方法和组合物 | |
CN107468938A (zh) | 一种芦笋茶的配方及其制备方法 | |
CN102091181A (zh) | 中药治疗急慢性粒细胞型白血病1组合及其制备方法 | |
CN105616961A (zh) | 一种中药辅助恶性肿瘤放化疗的药物及其制备方法 | |
CN105194433A (zh) | 一种内科治疗老年体虚症的中药组合物 | |
CN105287829A (zh) | 一种医治肾病综合征的中药组合物及制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180727 |